Stocks to Sell

Stocks can plunge for any number of reasons — investors may need to raise cash for large milestone purchases, or algorithms could be triggered by stop losses which create massive selloffs. Whatever the case, InvestorPlace’s journalists weed out the markets’ losers, keeping you informed of which stocks to cash out of before they come crashing down.

Peloton Stock Still Has No Place in a Legitimate Growth Portfolio

By Louis Navellier and the InvestorPlace Research Staff
Peloton’s big week continues the day after PTON stock popped on acquisition rumors, with CEO cut and big layoffs.

7 Russian Stocks at Risk of Being Roiled By the Ukraine Conflict

By Ian Bezek, InvestorPlace Contributor
Russia is flexing its military muscle once again. This could put these seven Russian stocks in serious jeopardy.

Grab Stock Is Not a Good Name to Latch Onto

By Larry Ramer, InvestorPlace Contributor
Investors should look for plays with less competition and more favorable markets than Grab. And Grab stock has just too high of a valuation.

A Buyout May Be the Best Hope for Clover Health Now

By Ian Bezek, InvestorPlace Contributor
The situation behind CLOV stock is spiraling from bad to worse. A sale of the company may be the only option to keep Clover Health running.

The ‘Discounted’ Price in NIO Stock Is a Lie

By Stavros Georgiadis, CFA, InvestorPlace Contributor
NIO stock continues to have key risks that do not make it a hot buy now. Its valuation remains too rich, and the firm continues to lose money.

StoneCo Stock Has Room to Fall Before it Hits Rock Bottom

By Louis Navellier and the InvestorPlace Research Staff
Expect the market to carry on sending STNE stock to lower prices. With no need to jump in, taking a hard pass on it is your best move.

GameStop’s NFT Pivot Is an Act of Desperation, Not Innovation

By Alex Sirois, InvestorPlace Contributor
GME stock is changing as the company is pivoting into NFTs, not that investors should care. It's still one to skip.

Is Beyond Meat Stock Beyond Help?

By Dana Blankenhorn, InvestorPlace Contributor
Beyond Meat continues to attract big partnerships and positive analyst coverage despite the poor performance of BYND stock.

Investors Have Cast Their ‘No’ Votes Against Bionano Genomics

By Louis Navellier and the InvestorPlace Research Staff
A preliminary report from Bionano Genomics doesn't tell the full story and a lack of profitability will likely weigh on BNGO stock.

Is Amazon Really That Strong Right Now?

By Alex Sirois, InvestorPlace Contributor
AMZN stock showed strength in its recent earnings report, but issues clearly exist for the tech giant despite the market's positive reception.

The Bull Thesis for C3.ai Is More Artificial Than Intelligent

By Louis Navellier and the InvestorPlace Research Staff
Even after some Wall Street experts slashed their price targets on AI stock, the most likely outcome will be disappointment and capital loss.

Can Production Ever Meet the Valuation of Lucid Group?

By Dana Blankenhorn, InvestorPlace Contributor
It's impossible to see how LCID stock justifies its $45 billion market cap, even if all of Lucid's production and sales dreams come true.

7 Triple-F-Rated Stocks That Have No Hope in Sight

By Louis Navellier and the InvestorPlace Research Staff
The contrarian in a lot of people perks up during selloffs like the one we're in right now, but don't let these F-rated stocks tempt you.

Your Late New Year’s Resolution: Avoid Peloton Interactive Stock

By Louis Navellier and the InvestorPlace Research Staff
Peloton had its moment in the first year of pandemic, and with PTON stock back down to 2019 levels the prospect of long-term growth is hazy.

Stoneco Is a Sinking Stone Drowning in Risk

By Joseph Nograles
STNE stock had been on a downtrend for much of 2021 for legitimate reasons. It has lost 86% of its value as Brazil enters into a recession.

Why Tilray Keeps Expanding and the Stock Keeps Suffering

By Steve Booyens, CFA
TLRY stock isn't necessarily an opportunity to buy the dip. Market forces will likely lead Tilray even lower before we see a recovery.

QuantumScape: Hindered by Lack of Near-Term Catalysts

By Ian Bezek, InvestorPlace Contributor
A cheaper price makes QS stock a little more attractive. Still, QuantumScape is hard to own given its lack of catalysts and uncertain long-term capabilities.

Bionano Is Not the Genomics Stock To Bet On

By Muslim Farooque, InvestorPlace Contributor
Bionano's recent results are lackluster and point to more volatility ahead for BNGO stock. Best to just avoid this stock for now.

7 Meme Stocks to Avoid as the Phenomenon Fades

By Josh Enomoto, InvestorPlace Contributor
While meme stocks were all the rage throughout 2021, it may be time to avoid this sector as the market grows tired of the antics.
Load More Articles